This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ortega, N. Articles by Plouet, J. Search for Related Content PubMed PubMed Citation Articles by Ortega, N. Articles by Plouet, J.

American Journal of Pathology, Vol 151, 1215-1224, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype

N Ortega, F Jonca, S Vincent, C Favard, MM Ruchoux and J Plouet
Laboratoire de Biologie Moleculaire Eucaryote, Toulouse, France.

The hypothesis that tumor growth is angiogenesis dependent has been documented by a considerable body of direct and indirect experimental data. A prerequisite for the development of novel anti-angiogenic agents is the design of drugs that would be active only on those endothelial cells with an angiogenic phenotype. We took advantage of the anti-idiotypic strategy to obtain circulating agonists specific for the vascular endothelial growth factor receptor KDR/flk-1 (J-IgG). They induced in the absence of VEGF cell proliferation in vitro and angiogenesis in the corneal pocket assay either through local or systemic delivery. Intraperitoneal injections of J-IgG in nude mice grafted with a prostatic adenocarcinoma led to tumor enlargement associated with an increase in both tumor vascularization and proliferation. In contrast KDR/flk-1 overstimulation had no detectable effect on normal tissues. These data underline that KDR/flk-1 is a functional marker of the angiogenic phenotype of endothelial cells.

This article has been cited by other articles:

				E. Im, A. Venkatakrishnan, and A. Kazlauskas Cathepsin B Regulates the Intrinsic Angiogenic Threshold of Endothelial Cells Mol. Biol. Cell, August 1, 2005; 16(8): 3488 - 3500. [Abstract] [Full Text] [PDF]

				M. A. Castilla, F. Neria, G. Renedo, D. S. Pereira, F. R. Gonzalez-Pacheco, S. Jimenez, P. Tramon, J. J. P. Deudero, M. V. A. Arroyo, S. Yague, et al. Tumor-induced endothelial cell activation: role of vascular endothelial growth factor Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1170 - C1176. [Abstract] [Full Text] [PDF]

				A. N. Witmer, B. C. van Blijswijk, C. J.F. van Noorden, G. F.J.M. Vrensen, and R. O. Schlingemann In Vivo Angiogenic Phenotype of Endothelial Cells and Pericytes Induced by Vascular Endothelial Growth Factor-A J. Histochem. Cytochem., January 1, 2004; 52(1): 39 - 52. [Abstract] [Full Text] [PDF]

				R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal EMAP-II Expression Is Associated with Macrophage Accumulation in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 1801 - 1806. [Abstract] [Full Text] [PDF]

				A. N. Witmer, J. Dai, H. A. Weich, G. F.J.M. Vrensen, and R. O. Schlingemann Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia J. Histochem. Cytochem., June 1, 2002; 50(6): 767 - 778. [Abstract] [Full Text] [PDF]

				A. N. Witmer, H. G. Blaauwgeers, H. A. Weich, K. Alitalo, G. F. J. M. Vrensen, and R. O. Schlingemann Altered Expression Patterns of VEGF Receptors in Human Diabetic Retina and in Experimental VEGF-Induced Retinopathy in Monkey Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 849 - 857. [Abstract] [Full Text] [PDF]

				P. Koolwijk, K. Kapiteijn, B. Molenaar, E. van Spronsen, B. van der Vecht, F. M. Helmerhorst, and V. W. M. van Hinsbergh Enhanced Angiogenic Capacity and Urokinase-Type Plasminogen Activator Expression by Endothelial Cells Isolated from Human Endometrium J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3359 - 3367. [Abstract] [Full Text] [PDF]

				N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1358 - C1366. [Abstract] [Full Text] [PDF]

				S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, J. O. Curwen, L. F. Hennequin, A. P. Thomas, E. S. E. Stokes, B. Curry, G. H. P. Richmond, et al. ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy Cancer Res., February 1, 2000; 60(4): 970 - 975. [Abstract] [Full Text]

				Y.-X. Chen, Y. Nakashima, K. Tanaka, S. Shiraishi, K. Nakagawa, and K. Sueishi Immunohistochemical Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Atherosclerotic Intimas of Human Coronary Arteries Arterioscler. Thromb. Vasc. Biol., January 1, 1999; 19(1): 131 - 139. [Abstract] [Full Text] [PDF]

				G. B. Whitaker, B. J. Limberg, and J. S. Rosenbaum Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121 J. Biol. Chem., June 29, 2001; 276(27): 25520 - 25531. [Abstract] [Full Text] [PDF]